Ufasomes for Targeted Delivery of Nintedanib in Lung Disease
Author Information
Author(s): Aboud Heba M., Ali Adel A., Mohammed Nada H., Hassan Ahmed H. E., Roh Eun Joo, El Menshawe Shahira F., Bao Yuping
Primary Institution: Beni-Suef University, Egypt
Hypothesis
Can Nintedanib-loaded ufasomes improve the bioavailability and therapeutic efficacy of the drug for treating idiopathic pulmonary fibrosis?
Conclusion
Ufasomes may serve as a promising method for non-invasive pulmonary delivery of Nintedanib, enhancing its therapeutic effects.
Supporting Evidence
- The optimal NTD-UFSs showed a cumulative release of 65.57% after 24 hours.
- Encapsulation efficiency was found to be 62.51%.
- Intratracheal administration of NTD-UFSs resulted in a significantly higher AUC0–∞ compared to oral and intratracheal NTD suspensions.
Takeaway
Researchers created tiny bubbles called ufasomes to help deliver a medicine for lung disease directly to the lungs, making it work better and safer.
Methodology
The study used Box–Behnken design for optimization and tested the ufasomes in a rat model for pharmacokinetics.
Potential Biases
Potential bias in the selection of experimental conditions and the small sample size.
Limitations
The study was conducted in a rat model, which may not fully represent human responses.
Participant Demographics
Male Wistar rats were used for the in vivo studies.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website